PLUS1
44.44
-0.22 (-0.49%)
-0.22 (-0.49%)
Upgrade to Real-Time
Afterhours
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Novavax Inc | NVAX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.41 | 0.93% | 44.66 | 42.88 | 46.66 | 44.08 | 44.25 | 17:40:27 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 44.44 | 44.60 | 0.16 | 0.36% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 50,973 | 5,705,895 | $ 44.68 | $ 254,934,641 | 11,961,808 | 3.54 - 61.4899 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:40:30 | formt | 126 | $ 44.44 | USD |
Novavax Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 2.62B | 58.65M | 56.18M | $ 18.66M | $ - | -5.62 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Novavax News
| Date | Time | Source | News Article |
|---|---|---|---|
| 6/03/2020 | 07:00 | PR Newswire (US) | Novavax Selects AGC Biologics to Manufacture Matrix-M™.. |
| 6/01/2020 | 16:15 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) |
| 5/29/2020 | 17:09 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 5/27/2020 | 08:00 | GlobeNewswire Inc. | Novavax Expands Large-Scale Global Manufacturing Capacity |
| 5/27/2020 | 07:40 | Dow Jones News | Geopolitical Power Play Over Coronavirus Vaccine Leaves.. |
| 5/26/2020 | 15:48 | Dow Jones News | Oil Rallies on Hopes for Economic Recovery -- Update |
| 5/26/2020 | 10:33 | Dow Jones News | Oil Rallies on Hopes for Economic Recovery |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NVAX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 46.10 | 53.97 | 40.50 | 47.35 | 8,325,651 | -1.44 | -3.12% |
| 1 Month | 17.3144 | 61.4899 | 16.92 | 43.66 | 14,757,194 | 27.35 | 157.94% |
| 3 Months | 9.51 | 61.4899 | 6.77 | 29.48 | 9,508,602 | 35.15 | 369.61% |
| 6 Months | 4.81 | 61.4899 | 3.6518 | 20.98 | 7,774,422 | 39.85 | 828.48% |
| 1 Year | 6.15 | 61.4899 | 3.54 | 19.54 | 4,301,408 | 38.51 | 626.18% |
| 3 Years | 20.20 | 61.4899 | 3.54 | 26.70 | 6,685,834 | 24.46 | 121.09% |
| 5 Years | 177.60 | 300.20 | 3.54 | 51.69 | 6,931,682 | -132.94 | -74.85% |
Novavax Description
| Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population. |
